Sathianathen Niranjan J, Krishna Suprita, Konety Badrinath R, Griffith Thomas S
Department of Urology, University of Minnesota, Minneapolis, MN, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Immunotherapy. 2017 Sep;9(12):1005-1018. doi: 10.2217/imt-2017-0051.
There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, no published Phase III PCa trials using immunotherapy only as a treatment has demonstrated direct antitumor effects by reducing prostate-specific antigen levels. Subsequently, the thought of combining immunotherapy with other treatment modalities has gained traction as a way to achieving optimal results. Based on data from other malignancies, it is hypothesized that radiotherapy and immunotherapy can act synergistically to improve outcomes. We will discuss the clinical potential of combining immune-based treatments with radiotherapy as a treatment for advanced PCa.
泌尿生殖系统恶性肿瘤的免疫治疗应用激增。免疫治疗是转移性肾细胞癌和非肌层浸润性膀胱癌的既定治疗方法，但其治疗前列腺癌（PCa）的潜力仍在研究中。尽管有报道称免疫治疗可带来生存益处，但尚无仅将免疫治疗作为一种疗法的已发表III期前列腺癌试验证明通过降低前列腺特异性抗原水平具有直接抗肿瘤作用。随后，将免疫治疗与其他治疗方式相结合的想法作为实现最佳效果的一种方法而受到关注。基于其他恶性肿瘤的数据，推测放疗和免疫治疗可协同作用以改善治疗效果。我们将讨论将基于免疫的治疗与放疗相结合作为晚期前列腺癌治疗方法的临床潜力。
